Pharmaron Beijing Co (SZSE:300759) Long-Term Debt : ¥6,922 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Long-Term Debt?

Pharmaron Beijing Co's Long-Term Debt for the quarter that ended in Mar. 2024 was ¥6,922 Mil.

Pharmaron Beijing Co's quarterly Long-Term Debt increased from Sep. 2023 (¥4,762 Mil) to Dec. 2023 (¥8,200 Mil) but then declined from Dec. 2023 (¥8,200 Mil) to Mar. 2024 (¥6,922 Mil).

Pharmaron Beijing Co's annual Long-Term Debt increased from Dec. 2021 (¥4,423 Mil) to Dec. 2022 (¥4,454 Mil) and increased from Dec. 2022 (¥4,454 Mil) to Dec. 2023 (¥8,200 Mil).

Pharmaron Beijing Co Long-Term Debt Historical Data

The historical data trend for Pharmaron Beijing Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Long-Term Debt Chart

Pharmaron Beijing Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

542.03

394.81

4,423.19

4,454.26

8,199.67

Pharmaron Beijing Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															4,507.74	4,704.68	4,761.82	8,199.67	6,922.19

Pharmaron Beijing Co (SZSE:300759) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pharmaron Beijing Co Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 17Q1:Germany

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Executives

Lou Xiao Qiang	Directors, executives
Zheng Bei	Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines